MX2023007399A - Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y usos de un inhibidor de kras g12c para el tratamiento de cancer. - Google Patents

Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y usos de un inhibidor de kras g12c para el tratamiento de cancer.

Info

Publication number
MX2023007399A
MX2023007399A MX2023007399A MX2023007399A MX2023007399A MX 2023007399 A MX2023007399 A MX 2023007399A MX 2023007399 A MX2023007399 A MX 2023007399A MX 2023007399 A MX2023007399 A MX 2023007399A MX 2023007399 A MX2023007399 A MX 2023007399A
Authority
MX
Mexico
Prior art keywords
inhibitor
kras
treatment
cancers
methyl
Prior art date
Application number
MX2023007399A
Other languages
English (en)
Inventor
Porta Diana Graus
Andrea Vaupel
Rainer Machauer
Saskia Maria Brachmann
Marc Gerspacher
Stefan Stutz
Edwige Liliane Jeanne Lorthiois
Bo Liu
Simona Cotesta
Catherine Leblanc
Robert Mah
Jeffrey Engelman
Rainer Wilcken
Christophe Mura
Pascal Rigollier
Nadine Schneider
Nicolas Warin
Vasileios Askoxylakis
Xiaoming Cui
Anna Farago
Andreas Weiss
Padmaja Yerramilli-Rao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2020/138339 external-priority patent/WO2022133731A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2023007399A publication Critical patent/MX2023007399A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere a una combinación farmacéutica que comprende un inhibidor de KRAS G12C, en particular, 1-{6-[(4M)-4-(5-Cloro-6-met il-1H-indazol-4-il)-5-metil-3-(1-metil-1H-indazol-5-il)-1H-pirazo l-1-il]-2-azaspiro[3.3]heptan-2-il}prop-2-en-1-ona (Compuesto A), o y uno más agentes terapéuticamente activos seleccionados de un inhibidor de SHP2 (p. ej. TNO155) y un inhibidor de PD-1; composiciones farmacéuticas que los comprenden; y métodos de uso de dichas combinaciones y composiciones en el tratamiento o la prevención de un cáncer o un tumor, en particular, donde el cáncer o el tumor está mutado en KRAS G12C.
MX2023007399A 2020-12-22 2021-12-20 Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y usos de un inhibidor de kras g12c para el tratamiento de cancer. MX2023007399A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2020/138339 WO2022133731A1 (en) 2020-12-22 2020-12-22 Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers
CN2021101546 2021-06-22
CN2021115387 2021-08-30
PCT/CN2021/139694 WO2022135346A1 (en) 2020-12-22 2021-12-20 Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers

Publications (1)

Publication Number Publication Date
MX2023007399A true MX2023007399A (es) 2023-07-06

Family

ID=82157381

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007399A MX2023007399A (es) 2020-12-22 2021-12-20 Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y usos de un inhibidor de kras g12c para el tratamiento de cancer.

Country Status (12)

Country Link
US (1) US20240082218A1 (es)
EP (1) EP4267134A1 (es)
JP (1) JP2023554471A (es)
KR (1) KR20230127256A (es)
CN (1) CN116710094A (es)
AU (1) AU2021408129A1 (es)
BR (1) BR112023012301A2 (es)
CA (1) CA3205008A1 (es)
IL (1) IL303917A (es)
MX (1) MX2023007399A (es)
TW (1) TW202241414A (es)
WO (1) WO2022135346A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202317100A (zh) * 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023199180A1 (en) * 2022-04-11 2023-10-19 Novartis Ag Therapeutic uses of a krasg12c inhibitor
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024102421A2 (en) 2022-11-09 2024-05-16 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020005063A (es) * 2017-11-15 2021-01-08 Mirati Therapeutics Inc Inhibidores de kras g12c.
MA52501A (fr) * 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
US10988485B2 (en) * 2018-05-10 2021-04-27 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11096939B2 (en) * 2018-06-01 2021-08-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MX2021002804A (es) * 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
WO2020165732A1 (en) * 2019-02-12 2020-08-20 Novartis Ag Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
US20220160706A1 (en) * 2019-02-12 2022-05-26 Novartis Ag Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
WO2021120890A1 (en) * 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents

Also Published As

Publication number Publication date
JP2023554471A (ja) 2023-12-27
TW202241414A (zh) 2022-11-01
AU2021408129A1 (en) 2023-07-13
BR112023012301A2 (pt) 2023-10-03
EP4267134A1 (en) 2023-11-01
WO2022135346A1 (en) 2022-06-30
CN116710094A (zh) 2023-09-05
US20240082218A1 (en) 2024-03-14
CA3205008A1 (en) 2022-06-30
KR20230127256A (ko) 2023-08-31
IL303917A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
MX2023007399A (es) Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y usos de un inhibidor de kras g12c para el tratamiento de cancer.
MX2021002804A (es) Terapias de combinacion.
MX2021011826A (es) Composiciones y combinaciones farmacéuticas que comprenden inhibidores del receptor de andrógenos y usos de estas.
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
MX2022003537A (es) Terapias de combinacion.
NO20052312L (no) Kombinasjonsprodukt av inhibitor fra SRC-familien av ikke-reseptor-tyrosinkinaser og gemcitabin.
MX2021002805A (es) Terapias de combinacion.
TNSN07385A1 (en) Therapeutic combination in case of benign prostate hyperplasia
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
MX2022001562A (es) Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).
NO20052380L (no) Beta-amino-heterosykliske dipeptidylpeptidaseinhibitorer for behandling og forhindring av diabetes
MXPA06001110A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer.
ATE322265T1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
WO2004037235A3 (en) Method and composition for preventing and treating solid tumors
AU2001275228A1 (en) Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
GB0107901D0 (en) Anti-cancer compounds
SG160323A1 (en) Methods for controlling angiogenesis and cell proliferation
MX2023009520A (es) Compuesto de 4-aminoquinazolina.
MX2022010306A (es) Epitopos y anticuerpos del homologo del oncogen viral del sarcoma de la rata kirsten (kras).
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
WO2007057440A3 (en) Improved methods of using phosphoantigen for the treatment of cancer
WO2004028474A3 (en) Caspase inhibitors as anticancer agents
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.
WO2022221528A3 (en) Kras g12c inhibitors